| P2093 | author name string | Kathryn M Hurren | |
| | Helen D Berlie | |
| P2860 | cites work | Hallucinogens | Q22251224 |
| | Actual Causes of Death in the United States, 2000 | Q22253001 |
| | Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure | Q24611940 |
| | Appetite suppressants and valvular heart disease - a systematic review | Q24802870 |
| | Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications | Q28139347 |
| | Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies | Q28217971 |
| | Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | Q28282364 |
| | Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension | Q28372978 |
| | Prevalence and trends in obesity among US adults, 1999-2008 | Q29547759 |
| | Central nervous system control of food intake and body weight | Q29619020 |
| | XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients | Q33974818 |
| | Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group | Q34062887 |
| | Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors | Q34086043 |
| | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects | Q34136304 |
| | Outcome success in obesity | Q34438273 |
| | Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity | Q34462886 |
| | The potential use of selective 5-HT2C agonists in treating obesity | Q34497896 |
| | Multicenter, placebo-controlled trial of lorcaserin for weight management | Q34660152 |
| | Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity | Q34728055 |
| | Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization | Q34746665 |
| | Central serotonin and melanocortin pathways regulating energy homeostasis | Q35173358 |
| | Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors | Q36509808 |
| | 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis | Q37073396 |
| | Pulmonary hypertension: therapeutic targets within the serotonin system. | Q37184405 |
| | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q42950914 |
| | Activation of central melanocortin pathways by fenfluramine | Q44079737 |
| | Annual medical spending attributable to obesity: payer-and service-specific estimates | Q44104253 |
| | Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women | Q46213450 |
| | Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake | Q57912931 |
| | Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice | Q60054745 |
| P433 | issue | 21 | |
| P921 | main subject | serotonin | Q167934 |
| | lorcaserin hydrochloride hemihydrate | Q27135478 |
| | lorcaserin hydrochloride | Q27888442 |
| P304 | page(s) | 2029-2037 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Lorcaserin: an investigational serotonin 2C agonist for weight loss | |
| P478 | volume | 68 | |